Current Hematologic Malignancy Reports

Papers
(The H4-Index of Current Hematologic Malignancy Reports is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas51
IDH Inhibitors in AML—Promise and Pitfalls33
MRD Assessment in Multiple Myeloma: Progress and Challenges31
Management of Ibrutinib Toxicities: a Practical Guide26
CAR-T Cell Therapy: the Efficacy and Toxicity Balance21
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments21
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib20
Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia17
Treatment-Free Remission: the New Goal in CML Therapy17
Enteropathy-Associated T cell Lymphoma16
Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms15
Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review15
Thrombocytosis and Thrombosis: Is There Really a Correlation?15
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies14
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders14
0.034715175628662